Efficacy and Safety of AAE581 in Postmenopausal Women With Osteopenia/Osteoporosis.

Efficacy and Safety of AAE581 in Postmenopausal Women With Osteopenia/Osteoporosis.

AAE581 is a specific inhibitor of the cysteine protease cathepsin K. This trial is designed to provide detailed information about the effects( efficacy and safety) of AAE581 on Bone Mineral Density.

Inclusion Criteria:

• Low spine Bone Mineral Density
• 0 to 1 prevalent fracture in non lumber spine

Exclusion Criteria:

• History or presence of any bone disease other than osteopenia /osteoporosis
• Previous treatment with other anti-osteoporosis agent(Wash out required)
• Evidence of vitamin D deficiency

Other protocol-defined inclusion/exclusion criteria may apply.